CRISPR-based gene editing technology is differentiated from other modalities, even traditional gene therapies, unlocking potential cures for a range of indications but also presenting unique developmental challenges. Devising a portfolio strategy for CRISPR-based gene editing therapies requires considering the novel therapeutic potential but also the technical, clinical, and commercial complexities. In this white paper, Health Advances proposes a framework for indication selection and portfolio strategy for CRISPR-based gene editing companies based on a range of factors including unmet need, level of competition, and addressable market size.
Unlocking Potential Cures with CRISPR: Indication Selection And Portfolio Strategy For CRISPR-Based Gene Editing Companies
Oct 06, 2021
By Jeff Bessen, Yinzi Liu, Christie Hung, Ned Wydysh, and Vivek Mittal
Posted by Health Advances LLC